Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

NCT07491172 is registered in ClinicalTrials.gov with CRISPR Therapeutics AG as lead sponsor.

NCT NCT07491172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07491172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias
Lead sponsor
CRISPR Therapeutics AG
Phase
Phase 1
Overall status
Recruiting
Start date
June 21, 2024
Completion date
June 30, 2028
Enrollment
90 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular, dyslipidemias, heterozygous familial hypercholesterolemia (hefh), homozygous familial hypercholesterolemia (hofh), hypercholesterolaemia, hypertriglyceridemia, lipid disorder, metabolic disease, mixed hyperlipemia, severe hypertriglyceridemia (shtg)